Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersHematology & Oncology Physician in Ashland, KY
NPI: 1306845474Primary Practice Location
KING'S DAUGHTERS' MEDICAL CENTER
2201 Lexington Ave, Ashland, KY
Primary Employer
Kings Daughters Tri State Hematology/Oncology
kingsdaughtershealth.com
HQ Phone
Get M.D. David's Phone Numberphone_androidMobile
Get M.D. David's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardOH State Medical License
KY State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 100 | 146 |
| 2 | 36415Insertion of needle into vein for collection of blood sample | 87 | 129 |
| 3 | 99215Established patient office or other outpatient, visit typically 40 minutes | 39 | 74 |
| 4 | 99213Established patient office or other outpatient visit, typically 15 minutes | 19 | 19 |
Authors: Jessica Mcfarlin, Laura Trice, Ravneet Thind
Journal: Support Care Cancer
Publication Date: 2024-09-02
Authors: Jessica Mcfarlin, Laura Trice, Ravneet Thind
Journal: Support Care Cancer
Publication Date: 2023-02-27
Lead Sponsor: ECOG-ACRIN Cancer Research Group
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Docetaxel, RADIATION: Radiation Therapy, DRUG: Paclitaxel, BIOLOGICAL: Trastuzumab, DRUG: Nab-paclitaxel, PROCEDURE: Lumpectomy, BIOLOGICAL: Trastuzumab Emtansine, PROCEDURE: Mastectomy, BIOLOGICAL: Pertuzumab
Lead Sponsor: SWOG Cancer Research Network
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Laboratory Biomarker Analysis, BIOLOGICAL: Tremelimumab, BIOLOGICAL: Durvalumab
Lead Sponsor: Alliance for Clinical Trials in Oncology
Collaborators: United States Department of Defense, National Cancer Institute (NCI), Bayer, Canadian Cancer Trials Group
Intervention / Treatment: OTHER: Placebo, DRUG: Aspirin
